Recent Company News

• 07:02 PM ET Dec 04, 2025
  

  Ascentage Pharma received FDA, EMA clearance to conduct global registrational Phase III study of olverembatinib in first-line treatment of Ph+ ALL (HK$60.85, 0.00)

• 06:38 AM ET Dec 02, 2025
  

  EQT Life Sciences portfolio company Egle Therapeutics initiates Phase 1 healthy volunteer study of EGL-003 as a potential treatment for atopic dermatitis (SEK 321.10, +1.00)

• 07:04 PM ET Nov 24, 2025
  

  Ascentage Pharma publishes olverembatinib Phase Ib data in gastrointestinal stromal tumors (HK$61.90, 0.00)

• 09:12 AM ET Nov 21, 2025
  

  Follow-up: FDA investigating death following treatment with Adzynma (¥4437.0000, 0)

• 09:08 AM ET Nov 21, 2025
  

  FDA investigating death following treatment with Adzynma (¥4437.0000, 0)

• 11:34 AM ET Nov 17, 2025
  

  FDA discloses paragraph IV patent certifications for Mirum Pharmaceuticals' Livmarli ($72.32, +0.88)

• 09:36 AM ET Nov 17, 2025
  

  StreetAccount Summary - Private company transactions for the week ended 15-Nov

• 07:04 AM ET Nov 17, 2025
  

  AbbVie announces LUPRON DEPOT (leuprolide acetate for extended-release injectable suspension) strength has received health Canada approval ($232.36, 0.00)

• 08:54 AM ET Nov 14, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:37 AM ET Nov 14, 2025
  

  EMA CHMP publishes summary of opinions for November 2025 meeting